Holen Sie sich die Stockscreener-App
14.94
0.67%
0.10
Handel nachbörslich:
14.94
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen - marketbeat.com
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance
Janux Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
71,016 shares tied to option exercise at JANX (NASDAQ: JANX) disclosed - stocktitan.net
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal - The Globe and Mail
Janux nominates development candidate under BMS collaboration - BioWorld MedTech
Bristol Myers Squibb (BMY) Partners with Janux on New Cancer The - GuruFocus
Janux Unveils Development Candidate in Bristol Myers Squibb Partnership, Worth $35M Milestone - Contract Pharma
Janux Therapeutics Expects $35 Million Milestone Payment From Bristol-Myers Squibb - Moomoo
Janux Therapeutics announces development candidate nomination under Bristol Myers Squibb collaboration - marketscreener.com
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration - TradingView
Janux Therapeutics, Inc. announced that, under its collaboration with Bristol Myers Squibb, it has officially nominated a development candidate drug. - Bitget
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb - Investing.com
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb By Investing.com - in.investing.com
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Yahoo Finance
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
Janux reports positive phase 1 results for JANX007 in mCRPC; stock down - MSN
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely - Moomoo
Janux Therapeutics (NASDAQ:JANX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Does Janux Therapeutics (NASDAQ:JANX) Show Signs of Market Sensitivity? - Kalkine Media
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
D-Wave Quantum: Die bittere Wahrheit! - Finanztrends
Advanced Renal Cell Carcinoma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeuti - Barchart.com
The Technical Signals Behind (JANX) That Institutions Follow - Stock Traders Daily
8th T-Cell Engager Therapeutics Summit - inewsource
Precision Trading with Janux Therapeutics Inc. (JANX) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Veeva Systems (VEEV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
HC Wainwright Expects Higher Earnings for Janux Therapeutics - MarketBeat
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
JANX PE Ratio & Valuation, Is JANX Overvalued - Intellectia AI
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside - DirectorsTalk Interviews
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Truist cuts Janux Therapeutics stock price target on competition By Investing.com - Investing.com Canada
Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating - marketscreener.com
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating - TipRanks
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Bitget
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st
Key facts: Janux Therapeutics Receives Strong Buy Ratings; Partners with BMS - TradingView
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating - TipRanks
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Guggenheim Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux Therapeutics, Inc. Q4 Loss Rises - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Janux Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q4 Revenue $0 - marketscreener.com
Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX) - Stock Titan
Janux Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
BRIEF-Janux Therapeutics Q4 Basic EPS USD -0.51 - TradingView
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Technical Reactions to JANX Trends in Macro Strategies - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS) - The Globe and Mail
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring A 376% Upside In Biotechnology - DirectorsTalk Interviews
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):